Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities

Brendan M. Ottemann, Austin J. Helmink, Wenting Zhang, Insiya Mukadam, Christopher Woldstad, James R. Hilaire, Yutong Liu, JoEllyn M McMillan, Benson J Edagwa, R Lee Mosley, Jered C Garrison, Bhavesh D. Kevadiya, Howard Eliot Gendelman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Antiretroviral therapy (ART) has changed the outcome of human immunodeficiency virus type one (HIV-1) infection from certain death to a life free of disease co-morbidities. However, infected people must remain on life-long daily ART. ART reduces but fails to eliminate the viral reservoir. In order to improve upon current treatment regimens, our laboratory created long acting slow effective release (LASER) ART nanoformulated prodrugs from native medicines. LASER ART enables antiretroviral drugs (ARVs) to better reach target sites of HIV-1 infection while, at the same time, improve ART's half-life and potency. However, novel ARV design has been slowed by prolonged pharmacokinetic testing requirements. To such ends, tri-modal theranostic nanoparticles were created with single-photon emission computed tomography (SPECT/CT), magnetic resonance imaging (MRI) and fluorescence capabilities to predict LASER ART biodistribution. The created theranostic ARV probes were then employed to monitor drug tissue distribution and potency. Intrinsically 111Indium (111In) radiolabeled, europium doped cobalt-ferrite particles and rilpivirine were encased in a polycaprolactone core surrounded by a lipid shell (111InEuCF-RPV). Particle cell and tissue distribution, and antiretroviral activities were sustained in macrophage tissue depots. 111InEuCF-PCL/RPV particles injected into mice demonstrated co-registration of MRI and SPECT/CT tissue signals with RPV and cobalt. Cell and animal particle biodistribution paralleled ARV activities. We posit that particle selection can predict RPV distribution and potency facilitated by multifunctional theranostic nanoparticles.

Original languageEnglish (US)
Pages (from-to)174-193
Number of pages20
JournalBiomaterials
Volume185
DOIs
StatePublished - Dec 2018

Fingerprint

Rilpivirine
Tissue
Magnetic resonance
Cobalt
Single photon emission computed tomography
Europium
Nanoparticles
Imaging techniques
Polycaprolactone
Tissue Distribution
Pharmacokinetics
Macrophages
Prodrugs
Therapeutics
HIV Infections
HIV-1
Viruses
Pharmaceutical Preparations
Lipids
Medicine

Keywords

  • Antiretroviral therapy
  • Biodistribution
  • Magnetic resonance imaging
  • Single photon emission computed tomography
  • Transformative nanotechnology

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Ottemann, B. M., Helmink, A. J., Zhang, W., Mukadam, I., Woldstad, C., Hilaire, J. R., ... Gendelman, H. E. (2018). Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials, 185, 174-193. https://doi.org/10.1016/j.biomaterials.2018.09.018

Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. / Ottemann, Brendan M.; Helmink, Austin J.; Zhang, Wenting; Mukadam, Insiya; Woldstad, Christopher; Hilaire, James R.; Liu, Yutong; McMillan, JoEllyn M; Edagwa, Benson J; Mosley, R Lee; Garrison, Jered C; Kevadiya, Bhavesh D.; Gendelman, Howard Eliot.

In: Biomaterials, Vol. 185, 12.2018, p. 174-193.

Research output: Contribution to journalArticle

Ottemann BM, Helmink AJ, Zhang W, Mukadam I, Woldstad C, Hilaire JR et al. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials. 2018 Dec;185:174-193. https://doi.org/10.1016/j.biomaterials.2018.09.018
Ottemann, Brendan M. ; Helmink, Austin J. ; Zhang, Wenting ; Mukadam, Insiya ; Woldstad, Christopher ; Hilaire, James R. ; Liu, Yutong ; McMillan, JoEllyn M ; Edagwa, Benson J ; Mosley, R Lee ; Garrison, Jered C ; Kevadiya, Bhavesh D. ; Gendelman, Howard Eliot. / Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. In: Biomaterials. 2018 ; Vol. 185. pp. 174-193.
@article{1be501b626de4f668aea000a2cc6f610,
title = "Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities",
abstract = "Antiretroviral therapy (ART) has changed the outcome of human immunodeficiency virus type one (HIV-1) infection from certain death to a life free of disease co-morbidities. However, infected people must remain on life-long daily ART. ART reduces but fails to eliminate the viral reservoir. In order to improve upon current treatment regimens, our laboratory created long acting slow effective release (LASER) ART nanoformulated prodrugs from native medicines. LASER ART enables antiretroviral drugs (ARVs) to better reach target sites of HIV-1 infection while, at the same time, improve ART's half-life and potency. However, novel ARV design has been slowed by prolonged pharmacokinetic testing requirements. To such ends, tri-modal theranostic nanoparticles were created with single-photon emission computed tomography (SPECT/CT), magnetic resonance imaging (MRI) and fluorescence capabilities to predict LASER ART biodistribution. The created theranostic ARV probes were then employed to monitor drug tissue distribution and potency. Intrinsically 111Indium (111In) radiolabeled, europium doped cobalt-ferrite particles and rilpivirine were encased in a polycaprolactone core surrounded by a lipid shell (111InEuCF-RPV). Particle cell and tissue distribution, and antiretroviral activities were sustained in macrophage tissue depots. 111InEuCF-PCL/RPV particles injected into mice demonstrated co-registration of MRI and SPECT/CT tissue signals with RPV and cobalt. Cell and animal particle biodistribution paralleled ARV activities. We posit that particle selection can predict RPV distribution and potency facilitated by multifunctional theranostic nanoparticles.",
keywords = "Antiretroviral therapy, Biodistribution, Magnetic resonance imaging, Single photon emission computed tomography, Transformative nanotechnology",
author = "Ottemann, {Brendan M.} and Helmink, {Austin J.} and Wenting Zhang and Insiya Mukadam and Christopher Woldstad and Hilaire, {James R.} and Yutong Liu and McMillan, {JoEllyn M} and Edagwa, {Benson J} and Mosley, {R Lee} and Garrison, {Jered C} and Kevadiya, {Bhavesh D.} and Gendelman, {Howard Eliot}",
year = "2018",
month = "12",
doi = "10.1016/j.biomaterials.2018.09.018",
language = "English (US)",
volume = "185",
pages = "174--193",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities

AU - Ottemann, Brendan M.

AU - Helmink, Austin J.

AU - Zhang, Wenting

AU - Mukadam, Insiya

AU - Woldstad, Christopher

AU - Hilaire, James R.

AU - Liu, Yutong

AU - McMillan, JoEllyn M

AU - Edagwa, Benson J

AU - Mosley, R Lee

AU - Garrison, Jered C

AU - Kevadiya, Bhavesh D.

AU - Gendelman, Howard Eliot

PY - 2018/12

Y1 - 2018/12

N2 - Antiretroviral therapy (ART) has changed the outcome of human immunodeficiency virus type one (HIV-1) infection from certain death to a life free of disease co-morbidities. However, infected people must remain on life-long daily ART. ART reduces but fails to eliminate the viral reservoir. In order to improve upon current treatment regimens, our laboratory created long acting slow effective release (LASER) ART nanoformulated prodrugs from native medicines. LASER ART enables antiretroviral drugs (ARVs) to better reach target sites of HIV-1 infection while, at the same time, improve ART's half-life and potency. However, novel ARV design has been slowed by prolonged pharmacokinetic testing requirements. To such ends, tri-modal theranostic nanoparticles were created with single-photon emission computed tomography (SPECT/CT), magnetic resonance imaging (MRI) and fluorescence capabilities to predict LASER ART biodistribution. The created theranostic ARV probes were then employed to monitor drug tissue distribution and potency. Intrinsically 111Indium (111In) radiolabeled, europium doped cobalt-ferrite particles and rilpivirine were encased in a polycaprolactone core surrounded by a lipid shell (111InEuCF-RPV). Particle cell and tissue distribution, and antiretroviral activities were sustained in macrophage tissue depots. 111InEuCF-PCL/RPV particles injected into mice demonstrated co-registration of MRI and SPECT/CT tissue signals with RPV and cobalt. Cell and animal particle biodistribution paralleled ARV activities. We posit that particle selection can predict RPV distribution and potency facilitated by multifunctional theranostic nanoparticles.

AB - Antiretroviral therapy (ART) has changed the outcome of human immunodeficiency virus type one (HIV-1) infection from certain death to a life free of disease co-morbidities. However, infected people must remain on life-long daily ART. ART reduces but fails to eliminate the viral reservoir. In order to improve upon current treatment regimens, our laboratory created long acting slow effective release (LASER) ART nanoformulated prodrugs from native medicines. LASER ART enables antiretroviral drugs (ARVs) to better reach target sites of HIV-1 infection while, at the same time, improve ART's half-life and potency. However, novel ARV design has been slowed by prolonged pharmacokinetic testing requirements. To such ends, tri-modal theranostic nanoparticles were created with single-photon emission computed tomography (SPECT/CT), magnetic resonance imaging (MRI) and fluorescence capabilities to predict LASER ART biodistribution. The created theranostic ARV probes were then employed to monitor drug tissue distribution and potency. Intrinsically 111Indium (111In) radiolabeled, europium doped cobalt-ferrite particles and rilpivirine were encased in a polycaprolactone core surrounded by a lipid shell (111InEuCF-RPV). Particle cell and tissue distribution, and antiretroviral activities were sustained in macrophage tissue depots. 111InEuCF-PCL/RPV particles injected into mice demonstrated co-registration of MRI and SPECT/CT tissue signals with RPV and cobalt. Cell and animal particle biodistribution paralleled ARV activities. We posit that particle selection can predict RPV distribution and potency facilitated by multifunctional theranostic nanoparticles.

KW - Antiretroviral therapy

KW - Biodistribution

KW - Magnetic resonance imaging

KW - Single photon emission computed tomography

KW - Transformative nanotechnology

UR - http://www.scopus.com/inward/record.url?scp=85054615234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054615234&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2018.09.018

DO - 10.1016/j.biomaterials.2018.09.018

M3 - Article

C2 - 30245386

AN - SCOPUS:85054615234

VL - 185

SP - 174

EP - 193

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -